Skip to Content
Investor Relations Reto Suter Chief Financial Officer
General Siegfried AG Untere Brühlstrasse 4
4800 Zofingen, Switzerland
Media Relations Affairs Peter Stierli Head Corporate Communications
Investor Relations Newsletter
Siegfried on Social Media
Close Page
Media Release

Siegfried begins construction of a new global R&D Center for Drug Substances in Evionnaz

From left: Sophia Dini (State Council Delegate for Economy and Innovation), Beat Rieder (Council of State VS, Die Mitte), Valerie Santacrocce-Tachini (President of the municipality Evionnaz), Wolfgang Wienand (CEO Siegfried), Marcel Signer (Site Head Siegfried Evionnaz), Irene Wosgien (COO DS Siegfried), Jürgen Roos (CSO Siegfried), Andreas Casutt (VRP Siegfried)

  • Siegfried broke ground to build a new global R&D Center for Drug Substances at its site in Evionnaz, Switzerland
  • Investment of up to CHF 25 million to strengthen Siegfried's Drug Substances network
  • The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
  • Siegfried, a leading global Contract Development and Manufacturing Organization (CDMO) headquartered in Zofingen, today broke ground for its new global Research and Development (R&D) Center for Drug Substances at its site in Evionnaz, Switzerland. The new R&D Center will begin its operations in 2024 and, together with the R&D Center in Zofingen, will significantly increase Siegfried's R&D capacity to drive future growth.

    At this new facility, for which Siegfried will invest up to CHF 25 million, more than 100 highly skilled specialists will work closely with Siegfried's customers to bring their precious innovations to industrial scale. The R&D Center will host advanced chemical and analytical facilities and state-of-the-art laboratories and will offer chemical process R&D and analytical development services for the entire Drug Substances network. With this project, Siegfried is further strengthening its site in Evionnaz, which is a key pillar within its global Drug Substances network.

    Wolfgang Wienand, CEO of Siegfried: "The new R&D Center in Evionnaz will strengthen our global network and highlights our commitment to offer the most advanced research and development services to our customers. It is an important milestone in our successful growth strategy and another major step on our path to become the leader in the CDMO space."

    About Siegfried

    The Siegfried Group is a global life sciences company with sites in Switzerland, Germany, Spain, France, Malta, the USA and China. In 2022, the company achieved sales of 1.229 billion Swiss francs and employed on 31.12.2022 more than 3'600 people at eleven sites on three continents. Siegfried Holding AG is publicly listed on SIX Swiss Exchange (SIX: SFZN).

    Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products (tablets, capsules, sterile vials, ampoules, cartridges and ointments) for the pharmaceutical industry and provides development services.


    Let’s get in touch

    Peter Stierli Head Corporate Communications